MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Strona główna・Stock List・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Closed

SectorHealthcare

34.24 -2.53

Buy Sell

Overview

Share price change

24h

Current

Min

34.06

Max

35.05

Key metrics
By Trading Economics
Income	9.6M 12M
Sales	10M 188M
P/E Sector Avg	32.613 35.739
Profit margin	6.374
Employees	357
EBITDA	14M 94M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+21.13% upside

Dividends
By Dow Jones
Next Earnings	6 lis 2025

Market Stats
By TradingEconomics
Market Cap	90M 1.1B
Previous open	36.77
Previous close	34.24

News Sentiment

By Acuity

78%

22%

345 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

27.09 / 27.6 Support & Resistance

Collegium Pharmaceutical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 paź 2025, 23:30 UTC

Hot Stocks

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 paź 2025, 21:21 UTC

Earnings

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 paź 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 paź 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 paź 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 paź 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 paź 2025, 22:54 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 paź 2025, 22:54 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 paź 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 paź 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 paź 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 paź 2025, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

2 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 paź 2025, 20:49 UTC

Acquisitions, Mergers, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 paź 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 paź 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 paź 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 paź 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 paź 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 paź 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 paź 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Comparison

Price change

Collegium Pharmaceutical Inc Forecast

Price Target

By TipRanks

21.13% upside

12 Months Forecast

Average 42.6 USD 21.13%

High 46 USD

Low 38 USD

Based on 5 Wall Street analysts offering 12 month price targets forCollegium Pharmaceutical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Collegium Pharmaceutical Inc - Dist in the past 3 months.

Technical Score

By Trading Central

27.09 / 27.6Support & Resistance

Bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

345 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.